linjc16/ctgov huggingface dataset:
Complete Nerve-Sparing Radical Hysterectomy for Cervical Cancer

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the feasibility of complete nerve-sparing type C1 radical hysterectomy in cervical cancer.

Detailed Description
-----------------
The primary objective of this study is to evaluate the rate of postvoid residual urine volume (PVR) <50ml on postoperative day 4 in patients with stage IB1 and IIA1 cervix cancer underwent complete nerve-sparing type C1 radical hysterectomy.

Official Title
-----------------
A Simplified Approach of Complete Nerve-sparing Type C1 Radical Hysterectomy for Cervical Cancer, a Phase II Study

Conditions
-----------------
Cervical Squamous Cell Carcinoma, Cervical Adenocarcinoma, Malignant Neoplasm of Cervix Stage IB1, Stage IIA1 Cervical Cancer

Intervention / Treatment
-----------------
* Procedure: Nerve-Sparing Radical Hysterectomy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age >=18 years to <= 70 years. Women with histologically confirmed, primary adenocarcinoma or squamous cell carcinoma of the uterine cervix. Stage IIA1, or IB1 disease. Karnofsky performance status >70. Patients who comply with follow-up. With written informed consent. Exclusion Criteria: Age>70 History of lower urinary tract damage or surgery. With abnormal urodynamic study results. Karnofsky performance status <70. Patients who have uncontrolled psychological disorders. Unwilling to or unable to comply with protocol. Prior treatment with pelvic radiotherapy

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Nerve-Sparing Radical Hysterectomy (NSRH)<br>Type C1 Hysterectomy | Procedure: Nerve-Sparing Radical Hysterectomy<br>* Type C1 NSRH Removal indwelling catheter on day 4 after surgery<br>* Other names: Fully Pelvic-Nerve Plexus Preserved;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proportion of patients with fully pelvic nerve plexus preserved | Proportion of patients who had a postvoid residual urine volume (PVR) under 50ml at postoperative day 4 | up to 30 days | 
| Proportion of patients removing indwelling catheter |  | up to 30 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The rate of 36-month local control |  | up to 36 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cervical cancer; Nerve-sparing hysterectomy; simplified
Morphological Pattern of the Atrophic Posterior Maxillae

Study Overview
=================
Brief Summary
-----------------
Overcoming the vertical and horizontal bone deficiency in the posterior maxillae are considered as the most challenging scenarios for implant-supported oral rehabilitation in modern implant dentistry. Therefore, a comprehensive and precise understanding of such anatomical structures are needed to avoid potential complications that ultimately might jeopardize the treatment outcome. Cone-beam computerized tomography (CBCT) offers some advantages to conventional CT-scan such as lower-dose radiation with high isotropic spatial resolution and cost. Therefore, it offers a viable and reliable tool to study anatomical structures such as the posterior atrophic maxillae

Conditions
-----------------
Bone Deficiency, Posterior Maxillae

Intervention / Treatment
-----------------
* Radiation: Cone-beam computed topography


Participation Criteria
=================
Eligibility Criteria
-----------------
Images were included if: Pristine maxillary posterior atrophic ridges (between premolars and molars) as a result of missing single or multiple teeth for over than 12 months. Residual ridge height (RH) was < 10 mm. Presence of teeth adjacent to or opposing the edentulous area so the location of the edentulous ridges corresponding to the tooth site could be identified. The maxillary sinus to be measured was visible from its floor to at least 15 mm from the alveolar crest of the edentulous ridge. Images were excluded if: Images were unclear or incomplete due to scattering or other reasons Edentulous ridge height was more than 10 mm Ridge preservation/augmentation simultaneous/delayed to tooth extractions Grafted maxillary sinus for implant-supported prosthesis The location of the edentulous ridge cannot be determined Implants or other prosthetic device restoring the posterior ridge Presence of sinus pathology that made the measurement impossible The outline of the edentulous ridge cannot be identified due to low 'grey scale' density

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Radiation: Cone-beam computed topography|This study used a retrospective database of preexisting data that included patients treated as part of routine periodontal and oral surgery therapy for each patient's needs. All the patients signed an inform consent approving using their radiographic data for research purposes.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Lateral Wall Thickness | Thickness measured in mm of the lateral aspect of the maxillary sinus | One month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Bone, Maxilla, Cone-Beam Computed Tomography, Regeneration
Evaluation of Implementation of the Phoenix PrEP (Pre-Exposure Prophylaxis) Access Project for Youth Aged 13-24

Study Overview
=================
Brief Summary
-----------------
This study will evaluate the implementation of a PrEP program for youth aged 13-24 in Phoenix, AZ. Numbers of youth who initiate PrEP, how long they continue with PrEP, and the barriers for youth who are trying to initiate and continue taking PrEP will be examined.

Detailed Description
-----------------
This observational study will describe the barriers encountered and the benefits found as youth engage in a PrEP program, the Phoenix PrEP Access Project and as they participate in PrEP provided through standard medical care. This study does not investigate the safety, efficacy or other medical benefits of PrEP, but looks at the issues surrounding youth who are trying to access PrEP.

Official Title
-----------------
Evaluation of Implementation of the Phoenix PrEP Access Project for Youth Aged 13-24

Conditions
-----------------
Unsafe Sex, IV Drug Usage

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria sexually active youth aged 13 through 24, at risk for contracting HIV, Negative for HIV as indicated by Negative Elisa and Western Blot (WB) or Negative 4th Generation test, weight greater than 35kg, offered PrEP to reduce the risk of contracting HIV. Exclusion Criteria Unknown or Positive HIV status, Renal Impairment as indicated by elevated BUN or Creatinine, abnormal urinalysis, Active infection with Hepatitis B Virus, Taking other medications containing Emtricitabine, Tenofovir or tenofovir alafenamide(TAF) such as Atripla, Complera, Emtriva, Genvoya, Odefsey, Stribild, and Viread taking drugs containing lamivudine, taking Hepsera, clinical symptoms consistent with acute viral infection within the past month.

Ages Eligible for Study
-----------------
Minimum Age: 13 Years
Maximum Age: 24 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PrEP Uptake | Uptake of PrEP offered to youth presenting for PrEP ages 13-24 | 3 years |
Alzheimer's Disease Genetics Study

Study Overview
=================
Brief Summary
-----------------
The purpose of the Alzheimer's Disease Genetics Study is to identify the genes that are responsible for causing Alzheimer's Disease (AD). One of the ways in which the risk factor genes for late onset AD can be investigated is by identifying and collecting genetic material from families with multiple members diagnosed with AD or dementia.

Detailed Description
-----------------
The purpose of the Alzheimer's Disease Genetics Study is to help identify the genes that may be responsible for causing Alzheimer's Disease (AD) by collecting genetic material from families with multiple members diagnosed with AD. Qualifying families will have two living blood-related individuals who have been diagnosed with or are showing symptoms of AD or dementia. Local study sites are located all over the United States, and arrangements may be made for eligible families who do not live near a participating site. The biological samples and data from these families will be made available to qualified researchers, who must sign a Materials Transfer Agreement (MTA) in order to protect the privacy rights of study participants before receiving samples and data.

Official Title
-----------------
National Centralized Repository for Alzheimer's Disease and Related Dementias (NCRAD)

Conditions
-----------------
Alzheimer Disease, Late Onset Alzheimer Disease, Dementia

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Two living family members diagnosed with AD or other dementia with any age of onset Biological samples available Fresh blood, or Immortalized lymphoblastic cell lines, or 3-5 grams of frozen cerebral cortex; fixed samples are not accepted Please note: this study does not include genetic counseling; because no personal identifying information such as name or date of birth is attached to samples, results of individual tests are not available to participants or family members. Exclusion Criteria: Does not meet inclusion criteria Member of a family that was included in the National Institute of Mental Health AD Genetics Sib Pair collection
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Distribute biological specimens to qualified investigators for use in their research studies. | Investigators will analyze the samples and publish de-identified results. These publications will help to further the knowledge in the field of dementia and potentially lead to new therapies and targets for therapies. | Contact investigators annually for an update on progress and publication status. | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Alzheimer disease, Late Onset Alzheimer disease risk factor genes, Genetics, Initiative, Dementia
Effects of Roaccutane on Ca, P, PTH and Vitamin D Metabolites in the Treatment of Sever Acne

Study Overview
=================
Brief Summary
-----------------
serum levels Ca, P, PTH and vitamin D metabolites before and after treatment with isotretinoin for sever acne

Detailed Description
-----------------
few studies has been done of serum levels Ca, P, PTH and vitamin D metabolites in patients receiving isotretinoin .In this study we measured serum levels Ca, P, PTH and vitamin D metabolites before and after treatment with isotretinoin for sever acne in 30 patients . the patients had no kown skeletal, endocrine ,renal and gastrointestinal disorders.

Official Title
-----------------
Effects of Roaccutane on Ca, P, PTH and Vitamin D Metabolites in the Treatment

Conditions
-----------------
Acne

Intervention / Treatment
-----------------
* Drug: isotretinoin (Roaccutane)


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: sever acne Exclusion Criteria: renal disorders gastrointestinal disorders skeletal disorders endocrine disorders drugs such as glucocorticoids , thiazide diuretics, mineral multivitamins, anti acids, tetracyclines
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: isotretinoin (Roaccutane)|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| serum levels of Ca, P, PTH and vitamin D metabolites and lateral chest x-ray before the treatment |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| serum levels of Ca, P, PTH and vitamin D metabolites and lateral chest x-ray after the treatment |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
acne, isotretinoin, calcium. vitamin D
755nm Alex Laser for Treatment of Stretch Marks

Study Overview
=================
Brief Summary
-----------------
Evaluate the safety and efficacy of the bilateral treatment of striae using a 755nm Alexandrite laser.

Conditions
-----------------
Striae

Intervention / Treatment
-----------------
* Device: 755nm Alexandrite Laser


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Is a healthy male or female between 18 and 85 years old. Has unwanted striae and wishes to undergo laser treatments to remove or improve them. Is willing to consent to participate in the study. Is willing to comply with all requirements of the study including being photographed, following post treatment care and attending all treatment and follow up visits. Exclusion Criteria Is hypersensitive to light exposure. Has active localized or systemic infection. Is taking medication(s) for which sunlight is a contraindication. Has a history of squamous cell carcinoma or melanoma. Has a history of keloid scarring. Has used oral isotretinoin (Accutane®) within 12 months of initial treatment or plans on using during the course of the study. Note: Skin must regain its normal degree of moisture prior to treatment. Has a history of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or use of immunosuppressive medications. Is female and pregnant, has been pregnant within the last 3 months, is currently breast feeding or planning a pregnancy during the study period. Is allergic to lidocaine, tetracaine or Xylocaine with epinephrine. Has any other reason determined by the physician to be ineligible to participate in the study.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 755nm Alexandrite laser with array handpiece<br>Device: 755nm Alexandrite laser with array handpiece | Device: 755nm Alexandrite Laser<br>* 755nm Alexandrite laser with array handpiece<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Photographic Evaluation of Striae Clearance | The physician will judge the overall improvement by selecting from improvement ranges of 0-25%, 25-50%, 50-75%, or 75-100% clearance when compared to the baseline. | Follow Up Between 1 and 3 Months Post Last Treatment |
Cameroon Mobile Phone SMS Trial

Study Overview
=================
Brief Summary
-----------------
The investigators hypothesize that sending weekly motivational text messages to people infected with HIV will encourage them to take their medication, compared to usual care.

Official Title
-----------------
Improving Adherence to HAART Using Mobile Phone Text Messages

Conditions
-----------------
HIV, Adherence

Intervention / Treatment
-----------------
* Other: Mobile phone text message
* Other: Usual care


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: On HAART for at least 1 month 21 years or more Owns a mobile phone Can read text messages Exclusion Criteria: On HAART for less than 1 month Aged less than 21 years

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Mobile phone text message<br> | Other: Mobile phone text message<br>* Weekly message with motivational content<br>* Other names: Text message;|
| Active Comparator: No Mobile phone text message<br>Usual care provided at clinic | Other: Usual care<br>* Usual care provided at clinic<br>* Other names: Routine care;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adherence | Measured using the Visual Analogue Scale, Self Report and Pharmacy Refill Data | Change from baseline at 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Weight |  | Change from baseline at 6 months | 
| Body Mass Index |  | Change from baseline at 6 months | 
| CDC classification |  | Change from baseline at 6 months | 
| WHO Classification |  | Change from baseline at 6 months | 
| Mortality | All cause mortality | 6 months | 
| CD4 count |  | Change from baseline at 6 months | 
| Viral load |  | Change from baseline at 6 months | 
| Quality of life | Measured using the SF-12 quality of life form | Change from baseline at 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
mobile phone, compliance, observance, SMS, text message, ARV, HAART, AIDS
Protect II, A Prospective, Multicenter Randomized Controlled Trial

Study Overview
=================
Brief Summary
-----------------
The IMPELLA® 2.5 System will be superior to Intra Aortic Balloon Pump in preventing the composite rate of major adverse events during and after the PCI procedure.

Official Title
-----------------
PROTECT II: A Prospective, Multi-center, Randomized Controlled Trial of the IMPELLA RECOVER LP 2.5 System Versus Intra Aortic Balloon Pump (IABP)in Patients Undergoing Non Emergent High Risk PCI

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Device: IMPLELLA LP 2.5
* Device: IABP Intra-aortic balloon pump


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Informed consent Subject is indicated for a NON emergent percutaneous treatment of at least on de novo or restenotic lesion in a native coronary vessel or bypass graft. Patient presents with: A compromised Ejection Fraction Intervention on the last patent coronary conduit Intervention on an unprotected left main artery or Patient presenting with triple vessel disease. Exclusion Criteria: ST elevation M.I. Pre procedure cardiac arrest within 24 hours. Subject in cardiogenic shock

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: IMPELLA LP 2.5<br> | Device: IMPLELLA LP 2.5<br>* Insertion of the LP 2.5 IMPELLA circulatory support system that can be placed across the aortic valve using a single femoral site. The device pumps blood from the left ventricle into the ascending aorta at 2.5 L/min.<br>|
| Active Comparator: IABP Intra-aortic balloon pump<br> | Device: IABP Intra-aortic balloon pump<br>* IABP uses counterpulsation to provide 0.2L/min coronary flow<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Composite rate of 10 major adverse events including death; MI;Stroke or TIA; and repeat revascularization. |  | 30 days +/- 10 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Maximum CPO decrease from baseline.Rate of in hospital major events compared between the IMPELLA and IABP. |  | In hospital events | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Patient undergoing scheduled PCI